XBiotech Inc. (XBIT)
Upgrades & Downgrades
Latest XBIT news
Why Are XBiotech Shares Trading Higher Today
28 April 2022
The French authority has signed off XBiotech Inc's (NASDAQ: XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French National Ca...
XBiotech Announces Payment of Dividend to Holders of Common Stock
30 July 2021
Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders
XBiotech Stock Increased 7.41%: Why It Happened
7 July 2021
The stock price of XBiotech Inc (NASDAQ: XBIT) increased by 7.41%. This is why it happened.
XBiotech Announces Dividend to Holders of Common Stock
6 July 2021
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to a...
XBiotech Announces Receipt of $75 Million from Sale of Antibody
30 June 2021
Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of P...
23 June 2021
XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Infla...
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
19 April 2021
The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Ph...
FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled S...
19 April 2021
XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer
Top Small-Cap Stocks for March 2021
26 February 2021
These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
21 January 2021
With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Strain...